Medicare to Negotiate Lower Prices for Weight-Loss Drugs
The government is expected to pay lower prices for Ozempic and Wegovy starting in 2027. The Trump administration will decide whether to expand coverage for millions of Americans.
Trump to lead Medicare drug negotiations
Now, Mr. Trump can build upon the provision in the Inflation Reduction Act that allows Medicare to negotiate prices on certain drugs. By pushing for tougher agreements with pharma
Medicare announces 15 new drugs chosen for price negotiations, including popular weight loss drug Ozempic
Diabetes and weight loss drugs Ozempic and Wegovy have been added to the list of medications selected for Medicare price negotiations, federal health officials announced Friday. At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
Ozempic, Ibrance among next drugs picked by Medicare for price talks
Announcing the 15 medicines chosen for the second round of negotiations is one of the Biden administration’s final health policy acts.
Ozempic and Wegovy selected for next round of Medicare drug price negotiations
Ozempic and Wegovy, the blockbuster but costly GLP-1 drugs often used for weight loss, are among the 15 medications that will be subject to<a class="excerpt-read-more" href=" More
Medicare targets popular weight loss drugs Ozempic, Wegovy for price negotiations
The Biden administration said Medicare will negotiate discounts with drug companies on 15 drugs prescribed to treat cancer, diabetes and asthma.
Medicare targets 15 more drugs for price negotiations — including Ozempic
On its last weekday in power, the Biden Administration has chosen the next batch of drugs up for price negotiation in Medicare.
Novo's Ozempic, Wegovy picked for US Medicare price negotiations
Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy are among the 15 drugs targeted for Medicare price negotiations for 2027, the U.S. government said on Friday, part of a law pharmaceutical companies have pledged to revisit with the Trump administration.
Investor's Business Daily on MSN13h
Here's How Donald Trump Could Shake Up Health Care — And Biotech Stocks
Biotech stocks have slumped 15% since Donald Trump won his second presidency. That's because Trump comes with a lot of ...
What Is Agenda47? What To Know About Trump’s Policy Agenda Before His Inauguration
Education: Trump’s proposals for K-12 schools include having parents elect school principals, cutting federal funding to any ...
Gallup: Many Americans skeptical about Trump helping lower cost of healthcare
President-elect Donald Trump faces deep skepticism that his administration's policies will make health care more affordable, ...
Johnson says no cuts to Social Security and Medicare to fund Trump's agenda
House Speaker Mike Johnson said cuts to Social Security and Medicare won't be part of the legislative plan being worked out ...
Medicare and telehealth: more restrictive rules could hit patients in 2025
Instead, people on Medicare won’t get the two years of continued coverage for telehealth appointments and five years’ for ...
Healthcare Dive4d
CMS proposes Medicare Advantage payment hike in 2026
The Biden administration’s last MA rule is a boon for insurers, though it remains to be seen how the incoming Trump ...
Employers outline health priorities under Trump
Groups representing employers that offer health insurance are gearing up to defend and try to bolster the largest source of ...
Social Security Update: Economist Warns Trump Plan May Speed Up Insolvency
Francois Melese warned in a recent op-ed of the damaging effects of Trump's plan to end Social Security taxes.